CORE--VIROLOGY

病毒学核心将作为一个集中的来源，以及 表征了HIV-1、HIV-2和SIV菌株的储备。 此外 到标准的原型实验室菌株， 将从充分表征的临床材料中提供分离株， 分子生物学核心将提供获得的遗传定义的分离株 通过感染性分子克隆的DNA转染。 股将是 在适当的宿主细胞（原代CD 4 +T细胞，单核细胞-巨噬细胞）中产生， 衍生的巨噬细胞或细胞系），等分，并在-80 ℃或 在液氮中。 核心将标准化表征 这些病毒（这应该提高参与的质量 CFAR研究单位），从而消除了许多重复工作。 将进行三个方面的表征：（1）病毒滴度 病毒株在相关宿主细胞中的表型;（2）病毒株的表型 (cell嗜性，合胞体诱导（SI）与非SI，细胞病变与 非细胞病变、复制动力学、药物敏感性等）;一个 (3)研究研究干预措施（基因）的影响 治疗、抗病毒化合物、抗体中和等）。 在 此外，核心将提供分离的CD 4+细胞和巨噬细胞， 在技术上很难准备。 这些核心的可用性 病毒库存和服务应扩大实验能力， 使用其服务的调查人员。

The Virology Core will serve as a centralized source for well characterized stocks of strains of HIV-1, HIV-2, and SIV. In addition to the standard, prototypic laboratory strains, the Specimen Banking Core will provide isolates from well-characterized clinical material and the Molecular Biology Core will provide genetically defined isolates obtained by DNA transfections of infectious molecular clones. Stocks will be produced in the appropriate host cell (primary CD4+T cells, monocyte- derived macrophages, or cell lines), aliquotted, and archive at -80 C or in liquid nitrogen. The Core will standardize the characterization of theses viruses (which should enhance the quality of the participating CFAR research units) and thereby eliminate much duplication of effort. Three areas of characterization will be performed: (1) tittering of viral strains in the relevant host cells type; (2) phenotyping of viral strains (cell tropism, syncytium-inducing (SI) versus non-SI, cytopathic versus non-cytopathic, replication kinetics, drug susceptibilities, etc.); an (3) studying the effects of investigational interventions (gene therapies, antiviral compounds, antibody neutralization, etc.). In addition, the Core will supply isolated CD4+ cells and macrophages, which are technically difficult to prepare. The availability of these Core viral stocks and services should extend the experimental capabilities of the investigators who use its services.